Tazarotene + Halobetasol Lotion for Psoriasis

Phase 4

Waitlist Available

Research Sponsored by Dermatology Consulting Services, PLLC

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 8 weeks

Awards & highlights

Study Summary

This trial is testing a new lotion to see if it can reduce psoriasis inflammation better than a common cream.

Eligible Conditions

Plaque Psoriasis

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 8 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~8 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Concentration of TNF-a and IL-17A in Psoriatic Plaques

Trial Design

2Treatment groups

Active Control

Group I: 0.01% Halobetasol and 0.045% Tazarotene LotionActive Control2 Interventions

0.01% Halobetasol and 0.045% Tazarotene Lotion (Duobrii)Applied to designated target plaque at bedtime.

Group II: Clobetasol Propionate 0.05% Cream (generic)Active Control1 Intervention

Clobetasol Propionate 0.05% Cream (generic)Applied to designated target plaque at bedtime.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Dermatology Consulting Services, PLLCLead Sponsor

2 Previous Clinical Trials

60 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what degree could 0.01% Halobetasol and 0.045% Tazarotene Lotion pose a risk to human health?

"There is ample regulatory approval for 0.01% Halobetasol and 0.045% Tazarotene Lotion, which resulted in a 3-out-of-3 score on our safety scale."

Answered by AI

Are there any vacancies for participants in this experiment?

"According to clinicaltrials.gov, this medical trial has fulfilled its recruitment quota and is no longer looking for candidates; the investigation was first posted on July 13th 2023 and had been edited most recently by September 16th of the same year. Despite not being a viable option at present, there are still 160 other studies requiring participants currently."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis

2023. "Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06042647.